Opinion on Genomics, Proteomics and Pharmacogenomics in Europe

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

RNAi: is the industry losing faith?

RNAi-based drugs were widely viewed as the next big thing after monoclonal antibodies; however, the initial wave of interest seems to be slowing down, largely due to financial constraints. Novartis and Roche recently ended their respective research in this field, highlighting the pharmaceutical industry's immediate need to boost its top line.

Published By Datamonitor
25 Nov 2010
Expert View
Expert View

The impact of IT on next-generation DNA sequencing

The mystery behind why some have a genetic disposition to a certain disease, or why a medicine works for some and not for others, might be revealed sooner than many had anticipated. In the past couple of months, several significant breakthroughs in DNA sequencing technology have been made, giving hope to the researchers that the coveted $1,000 genome is just around the corner.

Published By Datamonitor
21 Apr 2008
CommentWire
CommentWire

UK biotech: new heads for the biggest headaches

The UK's biotech leaders - Celltech, CAT, OGS and British Biotech - have all appointed or are about to appoint new CEOs. Not surprising, given the companies' recent poor results both in financial and drug development terms. The changes should signal a shift towards efficient drug development, and a new focus on profitable business development.

Published By Datamonitor
21 Nov 2002
CommentWire
CommentWire

Antisoma/Roche: a powerful alliance

Roche will take over the development of Antisoma's oncology products, including lead drugs Pentumomab and Therex. The deal, which could be worth over $500 million, should benefit both companies. It plugs gaps in Roche's near-term R&D pipeline, while giving Antisoma the benefit of Roche's development and marketing expertise.

Published By Datamonitor
18 Nov 2002
CommentWire
CommentWire

Novuspharma: lending a hand to Micromet

Novuspharma has agreed to co-develop Micromet's MT201, the only fully human antibody in development that targets the Ep-CAM molecule. The companies plan to begin phase II trials for the drug, across a wide range of cancers. Novuspharma's expertise and experience in oncology will aid MT201's development, but the companies will also need an experienced marketing partner.

Published By Datamonitor
02 Sep 2002
Expert View
Expert View

Licensing Week - August 9, 2002

Last week saw a flurry of licensing activity by Bristol-Myers Squibb, as the US-based big pharma extended its drug discovery relationships with Athersys and Exelixis. Genomics also featured heavily last week, as Pfizer, Oxagen, Fujisawa and Quark were all involved in genetic research deals. Finally, Serono signed another marketing deal, this time licensing rights to Genentech's Raptiva.<BR />

Published By Datamonitor
08 Aug 2002
CommentWire
CommentWire

Roche: T-20 demand will outstrip supply

Roche's new HIV drug, T-20, should launch next year. However, it already seems that producing sufficient quantities of T-20 will be a challenge - particularly before the full-scale production facility for the drug comes online. Roche will need to manage customer expectations carefully in the early stages of T-20's launch, or risk losing confidence.

Published By Datamonitor
06 Aug 2002
Expert View
Expert View

Multiple Sclerosis: the search for a vaccine continues

There are approximately 250,000 to 350,000 diagnosed cases of multiple sclerosis in the US, yet it is estimated that the actual number of Americans with MS may be even higher. As a new approach to the treatment of MS, vaccines have the potential to be both efficacious and cost effective. But can a vaccine be developed as a viable treatment for MS?

Published By Datamonitor
02 Aug 2002
Expert View
Expert View

D-day for diabetes drugmakers

Spanish researchers could be on the brink of curing type 1 diabetes. While this breakthrough is undoubtedly good news for patients, drugmakers could lose out, as the market vanishes before their eyes. But this could not be their biggest threat: anti-obesity drugs could stop people developing diabetes at all - is this the end for diabetes drugs?

Published By Datamonitor
17 May 2002
CommentWire
CommentWire

Diabetes: mice cured, now trying people

Although much further research is required, it could be viable to develop a genetic therapy for humans based on this discovery. While this could pose a threat to pharma companies in the $11.5 billion diabetes market, these firms are also in a strong position to exploit the new discoveries.

Published By Datamonitor
14 May 2002

« | 1 | 2 | 3 | » »|

No help is available.